Scorpion Biological Services has announced a planned development partnership to build a new 500,000-square-foot facility on Highway 24 east of Manhattan for large molecule and biologics manufacturing, with a particular focus on biodefense. Scorpion is a subsidiary of NightHawk Biosciences, a clinical stage biopharmaceutical company that develops novel biodefense assets and first-in-class therapies to modulate the immune system.
Once fully operational, Manhattan’s Scorpion facility is expected to employ more than 500 people. The initial average starting salary for employees is anticipated to be more than $75,000 per year, and the total capital investment is projected to be $650 million.
Scorpion’s President David Halverson said there is strong global demand for world-class biomanufacturing, and that the new facility will help Scorpion — which also has a facility in San Antonio — fill that demand. “We’re looking forward to rapidly growing and expanding Scorpion and Manhattan is the perfect location for our newest facility.”
Halverson pointed to the congruence of biodefense assets in Manhattan as key to the selection of the region as the location for their new facility.